(Informal 1-2 line summaries, which certainly should not be relied upon for legal or other research purposes)
-
- In this precedential decision, CAFC affirms antitrust violations for patents involving "carbon honeycombs, an activated carbon structure that can be used to
filter airborne pollutants in a variety of application" ("Specifically, the
’844 patent is directed to a dual-stage fuel-vapor canister
system that combines a higher-capacity gas-tank-side adsorbent with a lower-capacity vent-side adsorbent."). Defendant asserted that plaintiff required parties to purchase its (allegedly noninfringing) filters to receive a patent license and the jury below agreed. Plaintiff responds here:
- "First, Ingevity asserts a statutory patent misuse defense under § 271(d) of the Patent Act supported by the
related “staple article” doctrine;"
- "Second, Ingevity argues that its purported tying conduct is immune from antitrust liability under the patent
laws and Noerr-Pennington"; and
- "Third, Ingevity argues that the jury’s antitrust damages award should be vacated because BASF failed to disaggregate the damages caused by Ingevity’s unlawful
conduct from those resulting from its lawful patent enforcement and that such disaggregation was required and feasible"
Regarding 1), plaintiff argues that its alleged "tying" was merely control over of contributorily infringing product components ("35 U.S.C. § 271(d) . . . expressly shields conduct that would otherwise be characterized as tying or exclusionary when it is undertaken to
prevent contributory infringement as defined in § 271(c)."). However, CAFC finds that the jury considered the factual question whether the articles were contributorily infringing product components and had adequate grounds to conclude that they were not ("That testimony regarding honeycomb use in non-infringing air-intake systems,
together with the Park patent, gave the jury sufficient reason to discount Ingevity executives’ testimony and favor
BASF’s evidence . . . the jury’s verdict rested on permissible
inferences and credibility determinations supported by the
record, substantial evidence supports the finding that Ingevity’s honeycombs are staple goods").
Regarding 2), CAFC considers the argument here different from what was argued below ("Ingevity’s immunity argument
is no longer in the alternative; it now subsumes its patent misuse defense . . . We may not consider such
new and improperly preserved arguments . . . At summary judgment, Ingevity’s immunity argument
was based on the theory that what BASF had alleged as
tying conduct was actually mere patent enforcement activity and thus immune, and it further agreed that conduct
beyond mere enforcement activity was not immune . . . But now, for the first time on appeal, Ingevity erases
that distinction . . . It argues that even if the jury found
that its honeycomb products are staple goods, its tying conduct is still immune."). Accordingly, CAFC sets the new argument aside (n.b., the DCT's caution, cited approvingly by CAFC, that "the Noerr-Pennington doctrine
will [not] help Ingevity if BASF proves the Ingevity product . . . is a staple article of commerce").
Regarding 3), CAFC agrees with the DCT that "“[t]o establish an antitrust injury, BASF was not required to show that the accused conduct was the sole cause of its injury; BASF needed
to show that Ingevity’s conduct was a material or substantial cause of its injury.”" As the jury instructions and conclusions were consistent with that analysis ("In light of this evidence and Dr.
Mathur’s reliance on a broad set of record documents rather than speculative projections, the jury could reasonably have found both material causation and non-speculative
damages"), CAFC affirms.
-
- CAFC affirms utility noninfringement for "antiballistic armored panels having commercial and military
uses." Below, the DCT construed the preamble term "for resisting" as "requiring that the
“edge protection should function to resist edge impact penetrations at a level similar to the main body of the panel’s
resistance to penetrations of non-edge impacts”" resulting in noninfringement SJ. Here, "LTC argues that the district court erred in finding the
entirety of the preamble, including its “for resisting”
clause, is limiting." CAFC, however, agrees with the DCT that the preamble is limiting as the "specification emphasizes that the main purpose of the invention is to solve" the problem of delamination ("Treating the “for resisting” clause as limiting is needed to
ensure that the claim scope is commensurate with “what
the inventors actually invented and intended to encompass
by the claim."). CAFC contends that adopting the plaintiff's reading would instead read the term out of the claim ("[I]f adopted, it would render the “for resisting”
portion of the preamble essentially a nullity."). Ergo, after briefly confirming that there was procedural opportunity to contest the SJ ruling, CAFC affirms.
-
- CAFC provides a mixed infringement decision for claims involving "various intravascular blood pump systems and methods for providing heart support using intravascular blood
pump systems." Notably, CAFC disagrees with the DCT that various claim term interpretations were disclaimed "in related inter partes review proceedings, requiring “a narrower construction”" ("In
those IPR proceedings, Maquet distinguished its “elongate
lumen” claims from a prior art source, Jegaden,3 by arguing that “Jegaden provides a separate device—a catheter
with a guide wire—to guide an unmodified device into a
patient . . . Although
statements made by a patent owner during inter partes review can be relied on to support a finding of prosecution
disclaimer . . . “to invoke the doctrine of prosecution disclaimer, any such statements must ‘be both clear and unmistakable’” . . . Maquet’s
argument that Jegaden discloses using a separate catheter, which allegedly teaches away from modifying a cannula to accommodate a side lumen, does not rise to the requisite level of being “‘words or expressions of manifest exclusion or restriction’ in the intrinsic record.”"). Accordingly, CAFC vacates this portion of the decision below. However, CAFC agrees with the DCT that "guide mechanism" is a means-plus-function term ("[C]laim 16 is expressed solely in
functional terms—that is, the guide mechanism has the
function of “guid[ing] said intravascular blood pump and cannula to a predetermined location within the circulatory
system of a patient.”"), with the DCT's identification of corresponding structures in the specification, and with the DCT's conclusion that the target device does not infringe this structure ("the district court did not err in determining
that the Impella devices do not infringe claims 16 and 17
of the ’100 patent because no reasonable jury could have
found that Abiomed’s Impella devices contain a “guide
mechanism” under structure (b)"). Ergo, affirmed as to those portions.
-
- In this precedential decision, CAFC reopens the Alice analysis and finds the claims involving rendering guidance on a server of a variety of wireless devices ("a wireless device receiving from the server page descriptions and configuration data in a language readable by the device and at least partly within the device’s rendering capabilities, allowing the device to display the desired content."). Helpfully, "GoTV has simplified the ineligibility analysis required in this appeal. GoTV makes no separate arguments regarding eligibility for the three asserted patents; specifically, it nowhere argues that, if claim 1 of the ’865 patent is invalid for ineligibility, other asserted claims are eligible." Thus, after first addressing some claim construction issues ("We conclude that a relevant artisan, reading the claims
in the context of the specification, would understand “discrete low level rendering command” to mean a discrete
rendering command tailored based on the capabilities of
the user’s wireless device.") CAFC performs its 101 analysis:
". . . we conclude that the representative claim is directed to the abstract idea of a template set of specifications—generic in at least some respects (claim 1 requires only two such respects)—that can be tailored (in at least one respect) for final production of the specified product (here an image) to fit the user’s constraints . . . The claim’s calling for collecting and combining information for presentation to the rendering device does not
provide a focus on an advance in non-abstract ideas . . . the claim does not call
for an improvement in the wireless device’s rendering processes, which it takes as a given (hence the need for tailoring), merely supplying a final set of specifications for
rendering within the device’s constraints. Nor does the
claim call for any improvement in ordinary computer (here,
server) functions, such as receiving, storing, processing,
outputting, and transmitting."
Ergo, reversed for the defendant based upon invalidity (though vacated on some other issues).
-
- CAFC affirms 101 invalidity on claims "directed to the abstract idea of collecting, analyzing, retrieving, and displaying information,” specifically
by: “(1) collecting product-related information; (2) analyzing the product information (i.e., cross-referentially linking
the products); (3) receiving a product-location inquiry;
(4) retrieving product-location information in response to
the query; and (5) presenting the product-location information plus some additional information." CAFC iterates through the various claim elements, but doesn't find any elements reciting more than generic technical character ("Even though claim 1 of the ’933 patent requires
a “mobile device” and an “information storage device,” it
does not alter the analysis"). Specifications presenting technical problem-solutions sometimes save these cases, but CAFC finds no such mitigating statements here ("[T]he specification focuses on how to solve a business
problem using off-the-shelf technology, rather than an improvement to computer technology."). Finding no contrary indications at Step 2 ("Innovaport has not identified any inventive
concept arising from any claims, individually or in an ordered combination."), CAFC affirms.
James Skelley is a solo practitioner based in Mountain View, California since 2015, focusing primarily upon technology transactions and intellectual property procurement. James' practice also serves as an "incubator" for new legal service technologies / methodologies and a "living example" of their application. To this end, James regularly partners with larger law firms and with his clients so as to improve the practice of intellectual property law.
- Utility / Design / PCT Patent Prosecution
- Open Source Diligence
- Technology Transactions (typically as a team)
- Litigation / Inter Partes Review Support (typically as a team)
- James tends NOT to handle low-volume trademark work (though referrals are available)
- USPTO - #59458 - 10/16/2006
- California - #257829 - 12/01/2008
- District Columbia - #1014986 - 08/05/2013
- James is available by email, 8x8 hangout, and in-person meetups in the Valley.
- Email is typically the best way to reach James.
- Machine Learning / Robotics
- Cryptograpy / Cryptocurrency / Smart Contracts
- Medical Device
- Computational Biology (primarily modeling and proteomics)
- Signal Processing (primarily wireless and compression)
- Quantum Physics (primarily semiconductor) / Electromagnetics (antennae, waveguides, etc.)
- Manufacturing / 3D Printing
- James tends NOT to handle pure chemistry applications (though referrals are available), however James HAS handled matters involving computational proteomics, cellular modeling, and diagnostic lab protocols
LawMux Bites are (very) short, one-page summaries of various legal concepts, cases, and technologies. As informal summaries, you certainly shouldn't rely upon them as legal advice / for business use, but they can help orient you if you're new to the subject matter.